BioMed Research International
Volume 2019 (2019), Article ID 2682657, 8 pages
https://doi.org/10.1155/2019/2682657

Research Article

The Effects of Once-Weekly Dulaglutide and Insulin Glargine on Glucose Fluctuation in Poorly Oral-Antidiabetic Controlled Patients with Type 2 Diabetes Mellitus

Jie Wang,¹ Hui-qin Li,¹ Xiao-hua Xu,¹ Xiao-cen Kong,¹ Rui Sun,¹ Ting Jing,¹ Lei Ye,² Xiao-fei Su,¹ and Jian-hua Ma¹

¹Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210029, China
²National Heart Research Institute Singapore, National Heart Centre Singapore, Singapore

Correspondence should be addressed to Xiao-fei Su; suxiaofeifei@126.com and Jian-hua Ma; majianhua196503@126.com

Received 30 May 2019; Revised 30 July 2019; Accepted 10 August 2019; Published 25 December 2019

Academic Editor: Konstantinos Kantartzis

Copyright © 2019 Jie Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract.

Aim. To compare the effects of once-weekly Dulaglutide with once-daily glargine in poorly oral-antidiabetic controlled patients with type 2 diabetes mellitus (T2DM). Method. A total of 25 patients with T2DM admitted into Department of Endocrinology from December 2012 to August 2013 were randomly assigned into two groups: Dulaglutide group () and glargine group (). All patients received either Dulaglutide or glargine treatments for 52 weeks. Continuous glucose monitoring systems (CGMS) were applied to them for two 72 h periods at before and after the treatment each. Patient general clinical data were collected and analyzed. Result. Fast blood glucose (FBG) of the glargine group declined more significantly than the Dulaglutide group after treatment (). The mean blood glucose (MBG), standard deviation of blood glucose (SDBG), mean amplitude of glycemic excursion (MAGE) within a day, the largest amplitude of glycemic excursion (LAGE), -value, absolute means of daily difference (MODD) of glycemic excursion, the percentage of time (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9–7.8 mmol/L, and 9–10.0 mmol/L), maximum glycemic value, and minimum glycemic value were similar between the two groups (). The incidence of hypoglycemia was also similar between the two groups (). Though serum levels of TNF-α, IL-6, and 8-PGF2α all decreased, significant reduction was found in TNF-α and 8-PGF2α. TNF-α was only significantly reduced in the Dulaglutide group, while 8-PGF2α was seen in both groups. Conclusion. For T2DM patients with poorly controlled oral antidiabetic drugs, once-weekly Dulaglutide not only has the same effect on glucose fluctuation as once-daily glargine but also significantly reduced TNF-α and 8-PGF2α after a 52 week treatment protocol. This trial is registered with ClinicalTrials.gov NCT01648582.

1. Introduction

According to the International Diabetes Federation (IDF), it is estimated that the number of adult diabetes mellitus in China had reached 109 million, while the number of adult diabetes mellitus in the whole world had reached 415 million [1]. Most of them suffered from type 2 diabetes mellitus (T2DM), which is characterized by insulin resistance, hyperglycemia, and inadequate insulin secretion which results from progressive pancreatic β-cell function decline [2]. Currently, there are various drugs used to treat diabetes mellitus, including insulin secretagogues, insulin sensitizer, α-glucosidase inhibitor, insulin, or insulin analogues, dipeptidyl peptidase-4 (DPP-4) inhibitor, glucagon-like peptide-1 (GLP-1) analogues, and other oral antidiabetic drugs [3].

Recently, GLP-1 and its analogues have received more attention [4]. GLP-1 is a kind of incretin hormone secreted from L-cells of the intestine when blood glucose increases. Its receptor agonists, such as Exenatide, Liraglutide, Albiglutide, Lixisenatide, and Dulaglutide, activate corresponding signal transduction pathways by combining with GLP-1 receptors on the surface of cells [5]. Different from former GLP-1 receptor agonists which were usually injected 1-2 times a day, Dulaglutide is a new type of GLP-1 receptor agonist which can be injected subcutaneously once a week [6]. Dulaglutide activates GLP-1 receptors, improves glucose-dependent insulin secretion, lowers patient’s fasting blood glucose, suppresses the postprandial secretion of glucagon, reduces postprandial glucose, prolongs gastric emptying time, decreases appetite, and improves pancreatic β-cell functioning [7].

Recently, glucose fluctuation has been a new indicator in evaluating blood glucose [8]. By activating poly-metabolic pathways, glucose fluctuations can lead to microvascular and macrovascular complications [8]. Currently, few researches have been done on effects of GLP-1 receptor agonists 1–2 times per day on glucose fluctuations, and fewer have been done on effects of once-weekly drugs on glucose fluctuations.

Thus, the present study aims to determine the effect of Dulaglutide subcutaneous injection once a week with that of glargine injection once a day on glucose fluctuations of T2DM patients who were treated unsatisfactorily with metformin and/or sulfonylureas (SU) using the continuous glucose monitoring system (CGMS).

2. Methods

2.1. Subjects

This study was conducted at Department of Endocrinology; Nanjing Hospital affiliated to Nanjing Medical University, Nanjing. It was approved by the ethical committee of Nanjing Hospital. Written informed consent was obtained from all patients. Twenty-five patients with T2DM admitted into the Department of Endocrinology during the period between Dec. 2012 and Aug. 2013 were recruited as subjects of the present study. Patients were randomly assigned into two groups: the Dulaglutide group () and the glargine group (), and treated for 52 weeks. 72 h CGMS was applied at 3 days before starting and 3 days after completing the Dulaglutide or glargine treatments. The inclusion criteria were: (1) Patients were >18 years old; (2) Patients with diagnosed T2DM for at least 6 months based on the World Health Organization’s (WHO) criteria [9]; (3) Patients had been taking metformin and/or sulfonylurea for at least 3 months and have been taking them on a stable therapeutic dose (at least half the maximum dose) for at least 8 weeks; (4) Patients had a HbA1c level between 7.0% and 11.0%; (5) Patients had a Body Mass Index (BMI) level between 19.0 and 35.0 kg/m²; (6) Patients had stable body weight in the past 3 months. The data are stored at Department of Endocrinology; Nanjing Hospital affiliated to Nanjing Medical University, Nanjing and is available upon request.

The exclusion criteria were: (1) Patients had either been treated with a GLP-1 receptor agonist or a GLP-1 analogue, or is currently taking DPP-IV inhibitor and thiazolidinedione (TZD), or is currently taking insulin; (2) Patients had severe diabetic gastroparesis or have taken drugs that directly affect gastrointestinal motility for a long time; (3) Patients had one of the following diseases: acute or chronic hepatitis, acute or chronic pancreatitis, abnormal renal function, a serum calcitonin concentration higher than 20 pg/mL; (4) Patients had a history of malignancy.

2.2. Study Protocol

2.2.1. Anti-Diabetic Drugs

Sixteen patients were randomized to receive once a week 0.75 mg (11 cases) and 1.5 mg (5 cases) Dulaglutide (Dulaglutide group). Patients and physicians were blinded to the dose of Dulaglutide. Nine patients received daily glargine (Lantus, Germany) (Glargine group). If patients’ FBG ≥7.8 mmol/L, the initial dose of glargine was 6 unit/day (U/D). Insulin dose was adjusted once or twice weekly. The glargine algorithm had a treat-to-target strategy [10], based on the average of the previous three FBG values.

2.2.2. Patient General Data

Gender, duration of diabetes mellitus, height, weight, BMI, blood pressure (BP), heart rate, corrected QT interval of electrocardiogram (ECG), and therapeutic schemes were collected by blinded physicians.

2.2.3. CGMS

Before and after 52 weeks of treatment, we applied CGMS (Medtronic MiniMed, blind CGMS) to the two groups for 72 hours to monitor their continuous glucose. CGMS sensor was inserted under the patients’ abdominal skin and connected it to a glucose recorder to detect the glucose concentration of the interstitial fluid and have the data recorded. A mean value for each 5 minutes was stored and 288 measured values were recorded automatically every day with the glucose value, which can be effectively detected ranging from 2.2 to 22.2 mmol/L. The procedure was carried out for 72 hours. During the same period, capillary blood glucose levels of finger tips were measured at least 4 times a day to correct data from CGMS. The data were transmitted to a computer through an information collector and analyzed with the CGMS software 3.0. 2. Patients were required to have the same time for diet and the same volumes of excise food intake during the period of CGMS study. The definition of hypoglycemia: blood glucose is lower than 3.9 mmol/L of blood glucose and lasts for 15 minutes. Patients would measure finger peripheral blood glucose at least 4 times/day; record the incidence of hypoglycemia. Patients would be suggested to take food if blood glucose <3.9 mmol/L.

The following parameters were calculated:

(a)24 hours mean blood glucose (24  hours-MBG) and standard deviation of blood glucose (SDBG): the average level and SD of a total of 288 measured glucose values of 24  h with CGMS.(b)Mean amplitude of glycemic excursion (MAGE), the largest amplitude of glycemic excursion (LAGE), value and Absolute Means of Daily Difference (MODD).(c)Percentage time of hypoglycemia and hyperglycemia (≤2.8 mmol/L, ≤3.9 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L, 3.9–7.8 mmol/L, 3.9–10.0 mmol/L).(d) The maximum blood glucose(MAX-BG) and the minimum blood glucose (Min-BG).

2.2.4. Laboratory Examination

Fasting insulin (Ins 0) and fasting C-peptide (C-P0) were examined by chemiluminescence (Roche-E170, Roche, USA). HOMA-IR was calculated as Ins0 (μIU/mL) × Glu0 (mmol/L)/22.5. HbA1c was examined by High Performance Liquid Chromatography (HPLC: VARIANT2 Automatic hemoglobin tester, Biorad, USA). Index of biochemistry was examined by full automatic biochemical analyzer (Kodak 750, USA). Blood routine examinations were measured with automatic blood cell analyzer (Mindray DC-5380, China). Tumor necrosis factor-α (TNF-α) was measured using the humanspecifc Milliplex map kit (Millipore, St. Charles, MO, USA). Interleukin-6 (IL-6) was determined using commercially available Enzyme-Linked Immunosorbent Assay kits according to the manufacturer’s instructions (R&D Systems, Minneapolis, MN, USA). 8-iso prostaglandin F2α (8-iso PGF2α) was measured using an enzyme immunoassay method (Cayman Chemical Co., Ann Arbor, MI).

2.3. Statistical Analysis

All statistical analyses were done using the SPSS statistical program, version 22. Continuous variables were examined by t-test and were presented as mean ± standard deviation (SD). Nonnormal distributed data received the Mann-Whitney test and were presented with interquartile range (IQR). test was used to compare the categorical variables, and the statistical results were represented as -values and -values, and was considered significant.

3. Results

3.1. Patient General Data

There are no statistical differences found in history of diabetes mellitus (years), sex, age, body weight, BMI, BP, heart rate, ECG Corrected QT interval () between the two groups (Table 1) on week 0. No differences in body weight, BMI, BP, heart rate, and ECG Corrected QT interval () on the 52nd week were found (Table 1). After 52 weeks, changes of BMI were 0.09 (–0.69, 0.53) kg/m² in the Dulaglutide group and 0.73 (0.27, 1.37) kg/m² in the glargine group, respectively, and no statistically significant difference was found (). Other microvascular complications, other comorbidities and other treatments were similar between patients of two groups (Table 5).

Table 1: Clinical characteristics.

Dulaglutide group ()
Glargine group ()

Sex (female%)
Baseline
6 (37.50%)
4 (44.44%)

1

History (years)
Baseline
8 (5, 14.5)
5(3, 11.5)
−1.08
0.293

Age (years)
Baseline
59.88 ± 8.17
65.44 ± 11.09
−1.438
0.164

Height (cm)
Baseline
165.13 ± 7.48
159.44 ± 6.21
1.93
0.066

Weight (kg)
Baseline
68.97 ± 10.13
62.56 ± 5.72
2.023
0.055

52w
69.06 ± 9.85
64.67 ± 6.20
1.205
0.24

Body mass index (kg/m²)
Baseline
25.22 ± 2.67
24.63 ± 2.12
0.57
0.574

52w
25.26 ± 2.53
25.46 ± 2.30
−0.198
0.845

Systolic BP (mmHg)
Baseline
134.38 ± 13.93
133.67 ± 11.94
0.128
0.899

52w
134.69 ± 16.91
135.44 ± 10.00
−0.122
0.904

Diastolic BP (mmHg)
Baseline
80.06 ± 8.65
77.44 ± 8.53
0.73
0.473

52w
82.38 ± 8.98
77.89 ± 8.59
1.217
0.236

Heart rate (bpm)
Baseline
78.56 ± 7.20
73.33 ± 6.75
1.781
0.088

52w
77.50 ± 6.76
75.44 ± 11.25
0.574
0.571

Corrected QT interval
Baseline
438.52 ± 27.42
431.90 ± 18.22
0.636
0.531

52w
437.00 ± 26.59
427.44 ± 25.41
0.876
0.39

BP: blood pressure.

Table 2: Biochemical characteristics.

Dulaglutide group ()
Glargine group ()

Fasting blood glucose
Baseline
10.26 ± 2.84
10.72 ± 2.34
−0.418
0.68

(mmol/L)
52w
8.21 ± 1.70
6.92 ± 1.60
1.85
0.077

HbA1c (%)
Baseline
8.65 ± 1.57
8.73 ± 0.64
−0.186
0.854

52w
7.16 ± 1.17
7.40 ± 1.12
−0.507
0.617

Total amylase (U/L)
Baseline
69.44 ± 26.80
64.78 ± 17.35
0.467
0.645

52w
80.44 ± 29.98
59.44 ± 13.71
1.974
0.061

Pancreatic enzymes
Baseline
29.00 ± 7.91
28.22 ± 9.85
0.216
0.831

(U/L)
52w
30.50 (28.25, 37.50)
24.00 (20.00, 31.00)
−2.212
0.026

Lipase (U/L)
Baseline
43.94 ± 11.60
41.44 ± 14.15
0.477
0.638

52w
50.50 (38.50, 59.00)
37.00 (24.00, 55.50)
−1.728
0.087

Cholesterol (mmol/L)
Baseline
4.81 ± 1.04
4.67 ± 1.05
0.324
0.749

52w
4.68 ± 1.10
4.79 ± 1.35
−0.221
0.827

HDL-cholesterol (mmol/L)
Baseline
1.24 ± 0.21
1.31 ± 0.34
−0.654
0.52

52w
1.21 ± 0.28
1.13 ± 0.34
0.602
0.553

LDL-cholesterol (mmol/L)
Baseline
2.82 ± 0.81
2.54 ± 1.02
0.768
0.45

52w
2.68 ± 0.87
2.27 ± 0.80
1.168
0.255

Triglyceride (mmol/L)
Baseline
1.64 ± 0.87
1.97 ± 1.63
−0.655
0.519

52w
1.57 (0.88, 2.45)
1.50 (0.92, 5.866)
−0.142
0.901

Calcitonin (ng/L)
Baseline
2.24 ± 0.85
2.57 ± 0.73
−0.954
0.35

52w
2.13 ± 0.53
2.11 ± 0.33
0.103
0.919

Change
0 (0, 0)
−0.30 (−0.70, 0)
−2.074
0.052

White blood count (∗10⁹/l)
Baseline
6.36 ± 1.42
5.84 ± 1.37
0.889
0.383

52w
6.54 ± 1.48
6.19 ± 1.03
0.634
0.532

Haemoglobin (g/L)
Baseline
149.63  ±  11.77
139.89 ± 9.69
2.106
0.046∗

52w
147.63 ± 13.57
139.33 ± 10.71
1.573
0.129

Haematocrit (g/L)
Baseline
0.45 ± 0.04
0.42 ± 0.03
2.167
0.041∗

52w
0.45 ± 0.04
0.42 ± 0.03
1.706
0.102

Red blood count
Baseline
4.91 ± 0.35
4.46 ± 0.50
2.65
0.014 ∗

(∗10¹²/l)
52w
4.88 ± 0.39
4.52 ± 0.42
2.16
0.041

Platelet count (∗10⁹/L)
Baseline
207.63 ± 68.46
180.11 ± 40.20
1.266
0.218

52w
212.06 ± 59.10
195.33 ± 30.66
0.931
0.361

Blood urea nitrogen
Baseline
5.51 ± 1.34
5.55 ± 1.17
−0.078
0.938

(mmol/L)
52w
5.42 ± 1.19
5.43 ± 1.68
−0.021
0.984

Creatinine (μmol/L)
Baseline
73.50 ± 15.48
65.56 ± 12.51
1.314
0.202

52w
73.06 ± 16.34
66.78 ± 14.23
0.965
0.345

Alanine aminotransferase
Baseline
24.25 ± 13.93
17.67 ± 3.35
1.8
0.089

(U/L)
52w
21.00 (15.25, 36.50)
22.00 (14.50, 35.50)
−0.142
0.901

Glutamate aminotransferase
Baseline
20.38 ± 5.84
16.78 ± 4.21
1.62
0.119

(U/L)
52w
21.50 (18.00, 27.00)
23.00 (17.50, 25.50)
−0.199
0.857

Microalbumin
Baseline
22.50 (16.00, 52.25)
30.00 (11.00, 70.50)
−0.085
0.944

(mg/L)
52w
26.00 (9.25, 47.25)
41.00 (9.50, 61.50)
−0.538
0.607

Microalbumin/creatinine
Baseline
2.70 (1.13, 6.85)
3.80 (1.15, 12.45)
−0.566
0.588

(mg/g)
52w
3.30 (0.78, 4.55)
4.60 (1.25, 6.55)
−1.076
0.295

Fasting insulin (nmol/L)
Baseline
8.75 (5.30, 12.68)
7.90 (6.00, 14.00)
−0.113
0.923

Fasting C-peptide (nmol/L)
Baseline
0.52 ± 0.31
0.41 ± 0.20
0.888
0.384

HOMA-IR (%)
Baseline
0.93 ± 0.35
0.96 ± 0.38
−0.185
0.855

HOMA-IR: homeostatic model assessment of insulin resistance.

3.2. Laboratory Test

There are no statistically significant differences in FBG, HbA1c, Ins-0, C-P0, HOMA-IR, amylase, lipase, pancreatic enzymes, liver and renal function, blood lipid, blood routine (white blood cell, platelet) between the two groups at baseline. However, statistically significant differences were only in hemoglobin, hematocrit and red blood cell counting. No statistical differences were found between the two groups for any measured parameters after 52 weeks.

By comparing variations of data on the 53rd week with those at baseline levels, we found significant differences in FBG, total amylase, and lipase between the two groups. The reduction of FBG of the glargine group 3.7 mmol/L was significantly bigger than that of the Dulaglutide group’s (0.8 mmol/L, ). The reduction of HbA1c was similar in the two groups: the Dulaglutide reduced from 8.65 ± 1.5% to 7.16 ± 1.17%, while the glargine group reduced form 8.73 ± 0.64% to 7.40 ± 1.12%. The concentrations of total amylase and lipase of the Dulaglutide group rose more significantly than those of the glargine group. The concentration of total amylase of the Dulaglutide group increased from 69.44 ± 26.80 unit/L (U/L) to 80.44 ± 29.99 U/L, while that of the glargine group decreased from 64.78 ± 17.35 U/L to 59.44 ± 13.71 U/L. The concentration of lipase of the Dulaglutide group increased from 43.94 ± 11.60 U/L to 50.50 (38.50, 59.00) U/L, while that of the glargine group declined from 41.44 ± 14.15 U/L to 37.00 (24.00, 55.50) U/L (Table 2).

Table 3: CGMS results.

Dulaglutide group ()
Glargine ()

PT2.8
Baseline
0 (0, 0)
0 (0, 0)
0
1

52w
0 (0, 0)
0 (0, 0.50)
−1.925
0.054

AUC2.8
Baseline
0 (0, 0)
0 (0, 0)
0
1

52w
0 (0, 0)
0 (0, 0)
−1.333
0.182

PT3.9
Baseline
0 (0, 0)
0 (0, 0)
−0.15
0.88

52w
0 (0, 0)
0 (0, 8.00)
−0.446
0.656

AUC3.9
Baseline
0 (0, 0)
0 (0, 0)
0
1

52w
0 (0, 0)
0 (0, 0.05)
−1.925
0.054

PT3.9–7.8
Baseline
6.00 (0, 28.50)
10.00 (1.00, 33.00)
−0.605
0.545

52w
51.50 (27.00, 62.75)
44.00 (22.50, 66.50)
−0.482
0.63

PT3.9–10
Baseline
35.50 (4.25, 49.75)
36.00 (15.50, 53.50)
−0.34
0.734

52w
80.50 (66.00, 91.75)
56.00 (38.50, 86.50)
−1.359
0.174

PT10
Baseline
64.50 (49.50, 95.75)
64.00 (46.50, 84.50)
−0.34
0.734

52w
19.50 (8.00, 34.00)
25.00 (11.50, 54.50)
−1.048
0.295

AUC10
Baseline
2.05 (1.23, 4.50)
1.80 (1.05, 2.75)
−0.425
0.671

52w
0.30 (0.10, 1.28)
0.40 (0.10, 2.45)
−0.913
0.361

PT13.9
Baseline
25.00 (6.00, 41.25)
18.00 (8.00, 36.50)
−0.425
0.671

52w
0.50 (0, 11.50)
0 (0, 29.50)
−0.427
0.669

AUC13.9
Baseline
0.30 (0.03, 1.58)
0.30 (0.15, 0.45)
−0.23
0.818

52w
0 (0, 0.18)
0 (0, 0.65)
−0.513
0.608

MBG
Baseline
11.93 ± 3.00
11.26 ± 2.08
0.598
0.556

52w
8.63 ± 1.52
8.83 ± 2.00
−0.285
0.778

SDBG
Baseline
2.75 ± 0.65
2.67 ± 0.60
0.317
0.754

52w
2.24 ± 0.95
2.91 ± 1.31
−1.486
0.151

MAX
Baseline
17.70 ± 2.92
17.18 ± 2.31
0.46
0.65

52w
14.43 ± 3.47
15.14 ± 3.90
-0.472
0.641

MIN
Baseline
7.19 ± 2.70
6.43 ± 2.46
0.697
0.493

52w
5.06 ± 1.21
4.46 ± 1.62
1.065
0.298

Change
−2.30 (−3.08, −0.15)
−2.60 (−4.15, 1.25)
−0.17
0.865

LAGE
Baseline
10.52 ± 1.85
10.74 ± 1.85
−0.29
0.775

52w
8.98 ± 3.76
10.69 ± 3.86
−1.078
0.292

MAGE
Baseline
6.74 ± 1.99
6.88 ± 2.20
−0.157
0.877

52w
5.86 ± 2.81
7.09 ± 3.21
−0.997
0.329

-Value
Baseline
26.76 (16.31, 58.85)
24.80 (16.04, 34.97)
−0.481
0.63

52w
5.19 (2.47, 14.96)
10.75 (4.42, 33.65)
−1.585
0.113

MODD
Baseline
2.33 ± 1.33
2.33 ± 0.83
0.002
0.999

52w
1.91 ± 0.90
2.19 ± 0.62
−0.82
0.424

PT: Percentage time of blood glucose; AUC: area under the curve; MBG, mean blood glucose; SDBG: standard deviation of blood glucose; MAX: the maximum blood glucose; MIN: the minimum blood glucose; LAGE: the largest amplitude of glycemic excursion; MAGE: mean amplitude of glycemic excursion; MODD: absolute means of daily difference.

3.3. CGMS Data

There are no statistically significant differences found in MBG, SDBG, LAGE, MAGE, -Value, MODD, and PT (≤2.8 mmol/L, ≤3.9 mmol/L, 3.9–7.8 mmol/L, 3.9–10.0 mmol/L, ≥10.0 mmol/L, ≥13.9 mmol/L). Max-BG or Min-BG either on baseline or after 52 weeks were similar (). The two groups’ variations in 24 h-MBG from baseline levels were −2.95 (−4.23, −1.93) for the Dulaglutide group and −3.50 (−4.85, 0.55) for the glargine group, respectively, with no statistically significant differences. Variations from baseline levels of the two groups in MAGE were −1.79 (−3.68, 2.74) for the Dulaglutide group and 0.32 (−2.88, 3.21) for the glargine group, but no statistically significant differences were found (Table 3).

Table 4: Oxidative stress and inflammatory profile.

Variable

Dulaglutide group ()
Glargine group ()

TNF-a (pg/ml)
Baseline
7.23 (5.92, 8.74)
5.82 (4.89, 7.02)

52w
5.1
5.96 ± 1.35

IL-6 (pg/ml)
Baseline
0.87 ± 0.46
0.95 (0.51, 1.72)

52w
0.64 ± 0.39
0.61 (0.51, 1.08)

PGF-2a (pg/ml)
Baseline
12.28 (10.71, 26.54)
11.05 (7.34, 17.97)

52w
9.24
5.60

vs. baseline.

Table 5: Microvascular complications and other treatments.

Variable
Baseline

Week 52

Dulaglutide ()
Glargine ()

Dulaglutide ()
Glargine ()

Diabetic nephropathy, (%)
3
2
0.835
3
3
0.412

Other comorbidities, (%)

 Hyperlipidemia
5
4
0.509
6
4
0.734

 Hypertension
11
5
0.509
11
5
0.509

Other treatments, (%)

 CCB
4
3
0.656
4
3
0.656

 ACEI/ARB
5
2
0.629
5
2
0.629

 Beta-blockers
2
0
0.260
2
0
0.260

 Statins
3
2
0.835
4
2
0.876

CCB: calcium channel blockers; ACEI/ARB: angiotensin-converting enzyme inhibitor and/or angiotensin II receptor blocker.

3.4. Oxidative Stress and Inflammatory Profile

To determine the effect of different drug treatments on oxidative stress and inflammation, we measured TNF-α, IL-6, and 8-PGF2α. Patients in all groups had higher inflammatory cytokine levels at baseline. After 52 week treatment, TNF-α levels significantly decreased in the Dulaglutide group () (Table 4); however, this was not seen in the glargine group. Though there were trends of IL-6 to reduce, no significant difference was found in both groups at 52 weeks compared with those at baseline. Serum 8-PGF2α levels significantly decreased in both the Dulaglutide and glargine groups after 52 week treatment as compared with baseline () (Table 4). There were no significant differences found between groups at 52 weeks after treatment.

4. Discussion

The present study showed that that addition of once-weekly Dulaglutide has the same effect as once-daily glargine on control of glucose fluctuations and oxidative stress and inflammation in patients with T2DM, who were poorly controlled by oral antihyperglycemic medications.

As a GLP-1 receptor agonist, Dulaglutide consists of GLP-1(7–37) covalently linked to an Fc fragment of human IgG4, thereby protecting the GLP-1 moiety from inactivation by dipeptidyl peptidase 4. The average biological half-life of Dulaglutide is 90 h, making it an ideal candidate for delivery once a week. Currently, few studies have been done on the effects of Dulaglutide on glucose fluctuation, among which the AWARD-4 trial studied Dulaglutide in 884 patients with T2DM [11]. The patients were randomly assigned to receive a 52 week combinational treatment of insulin lispro with once-weekly Dulaglutide or once-daily glargine with insulin lispro. It showed that Dulaglutide in combination with lispro resulted in a significantly greater improvement in glycemic control than glargine did. A substudy of this patient cohort () received CGMS on weeks 0, 13, 26, and 52, respectively, to monitor blood glucose fluctuation [12]. It showed that the reduction of 24 hours MBG was similar among the three groups at weeks 26 and 52. Though the percentage of time (PT) of normoglycaemia (3.9–7.8 mmol/L) was similar, the percentage of near-normoglycaemia of the Dulaglutide-1.5 mg group (3.9–10.0 mmol/L) was higher than the glargine group on week 26. However, the PTs of normoglycaemia and near-normoglycaemia were similar on week 52. It suggested that the once-weekly Dulaglutide treatment has similar effects on glucose control to that of the once-daily glargine treatment. The study by Probstifield [13], applied CGMS to 102 T2DM patients with high cardiovascular risk to determine blood fluctuation in patients received basal insulin with twice-daily Exenatide or with bolus insulin after 26 weeks. It was found that the indexes of the two groups had similar MAGE and SD.

Hypoglycemia is the most common adverse events, and severe hypoglycemia was closely correlated to mortality [14, 15]. In the present study, the occurrence of hypoglycemia of the Dulaglutide group was similar to that of the glargine group. This is consistent with AWARD-3 and -5 studies, which did not find difference in occurrence of hypoglycemia in Dulaglutide injection and oral-drug taking groups [16, 17]. Comparing the effects of the short-acting Exenatide with that of the fast-acting insulin on hypoglycemia, Jeffery’s study did not find significant differences between the two treatments [13]. Instead, the AWARD-4 sub-study found that the glargine group had a higher rate of nocturnal hypoglycemia on week 26. However, the percentage time of hypoglycemia of the glargine group (PT ≤ 3.9 mmol/L) was significantly higher than the Dulaglutide group on week 52, suggesting that the Dulaglutide group had less incidence of hypoglycemia. The AWARD-4 trial found that on weeks 26 and 52, the total rate of hypoglycemia was similar between groups [11]. Similarly, AWARD-2 trial [18] found that on week 52, the total rate and the total times of hypoglycemia and nocturnal hypoglycemia of the glargine group were all higher than those of Dulaglutide groups. Araki et al. [19] found that the total rate of hypoglycemia and nocturnal hypoglycemia of the glargine group were higher on week 26 in Japanese population. Thus, it seems that Dulaglutide has better control on hypoglycemia as compared with glargine.

Abdul–Ghani et al. [15], randomly assigned 231 poorly glycemic-controlled T2DM patients to receive once a week Exenatide/pioglitazone combinational treatment or basal/bolus insulin group for 18 months. They found the rate of hypoglycemia in patients received basal/bolus insulin injection was threefold of that of the patients in the combinational group. Diamant et al. [22] randomly assigned 586 T2DM patients to once-weekly albiglutide group or thrice-daily prandial insulin lispro group. Compared with that of the insulin group, the weekly combinational therapy group had less incidence of hypoglycemia [20]. The present study showed that the occurrence of hypoglycemia of the Dulaglutide group was similar to that of the glargine group, but was different from the Abdul–Ghani’s study [15]. It might be due to the different treatments applied in the present study, as higher risk of hypoglycemia may be associated with basal/bolus insulin injection as compared with oral anti-diabetic drugs. Different population races and diet habits may also contribute to the difference.

The present study found that FBG of the glargine group decreased significantly than that of the Dulaglutide group on week 52. AWARD-2 trial [18] compared the safety and efficacy of Dulaglutide (0.75 mg or 1.5 mg) with that of glargine in combination with metformin and Glimepiride. FBG of the glargine group declined more than the Dulaglutide 0.75 mg group on week 52 on AWARD-2. Similarly, AWARD-4 trial found that the FBG of the glargine group declined more on weeks 26 and 52. FBG in the current study was consistent with them, but was different from Araki study in which the FBG of the Dulaglutide group was similar to that of the glargine group on weeks 14 and 26 [19]. The differences may be due to the difference patient population selected in this study and different treatment protocol.

In the present study, HbA1c of the Dulaglutide group declined to a similar level to that of the glargine group on week 52. This is consistent with others [12, 13]. Araki et al. [19] even found that the HbA1c of the Dulaglutide group declined more than that of the glargine group. This might be due to differences in patient population selection and treatment protocol. The present study found that the Dulaglutide group had a similar rate of HbA1c-control (percentage of HbA1c ≤ 6.5% and HbA1c ≤ 7%) to that of the glargine group on week 52. This is consistent with AWARD-4 study which found no statistical differences in rate of HbA1c-control of the three groups [11]. On the contrary, Abdul-Ghani et al. [15] found that higher rates of HbA1c-control were all seen in the weekly-Exenatide group. The difference might be due to differences in clinical protocol, race and sample size.

Decreased oxidation stress and inflammation markers decreased in both groups after 52 weeks’ treatment, notably in Dulaglutide group. This suggests that both treatments have anti-inflammatory and oxidative stress effects in T2DM and Dulaglutide has more effective therapeutic efficacy in reducing inflammation in T2DM.

Body weight reduction has been seen in both Dulaglutide and Exenatide treatments [7, 11, 18, 19, 22], Abdul-Ghani found that the body weight gain of the weekly-Exenatide group was only half of that of the control group, with the difference being of statistical significances in Qatar study [15]. Other studies found body weight loss of the Dulaglutide group [11, 18, 19]. Some studies [20, 22] found, when comparing glucose control of once-weekly-albiglutide with that of glargine and comparing twice-daily Exenatide with that of glargine, and found that patients received Exenatide had significant lower body weight. In the present study; however, no significant differences in body weight reduction was found between the two groups at week 52. This might be due to the small sample-size of the present study.

Studies showed increase in amylase, lipase, and pancreatic enzymes in AWARDs studies and Araki’s studies [11, 16–19, 23]. The present study also found that the amylase and lipase of the Dulaglutide group increased significantly as compared with those of the glargine group. However, we did not find statistically significant differences in pancreatic enzymes of the two groups. These were consistent with Araki’s studies [19]. No adverse events such as acute pancreatitis, pancreatic carcinoma etc., were found during study course [24]. The mechanism of pancreatic enzymes might be due to the increased replication of pancreatic duct cell with obesity and T2DM [25].

The study has several limitations. Firstly, the sample size is small. Secondly, the mechanism of Dulaglutide on reduction of inflammatory biomarkers is unknown. Future study is needed to explore the underlined mechanism.

In conclusion, for T2DM patients with poorly controlled oral antidiabetic drugs, once-weekly Dulaglutide not only has the same effect on glucose fluctuation as once-daily glargine, but also significantly reduced TNF-α and 8-PGF2α after a 52-week treatment protocol.

Data Availability

The data are restricted to researchers approved by ethical committee of Nanjing Hospital affiliated to Nanjing Medical University, Nanjing. Other researcher may access the data upon request and approval of ethical committee of Nanjing Hospital affiliated to Nanjing Medical University, Nanjing.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jie Wang and Hui-qin Li are equally contributed.

Acknowledgments

The study was supported by the fund of Scientific and Technological Development Program of Jiangsu Province of China (BL2014010).

References

K. Ogurtsova, J. D. da Rocha Fernandes, Y. Huang et al., “IDF diabetes atlas: global estimates for the prevalence of diabetes for 2015 and 2040,” Diabetes Research and Clinical Practice, vol. 128, pp. 40–50, 2017.

J. L. Leahy, “Pathogenesis of type 2 diabetes mellitus,” Archives of Medical Research, vol. 36, no. 3, pp. 197–209, 2005.

X. Sha, N. Wang, and X. Deng, “Reasearch progress of GLP-1 and its analogues. Strait,” Pharmaceutical Journal, pp. 1–6, 2011.

L. L. Baggio and D. J. Drucker, “Biology of incretins: GLP-1 and GIP,” Gastroenterology, vol. 132, no. 6, pp. 2131–2157, 2007.

W. Glaesner, A. M. Vick, R. Millican et al., “Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein,” Diabetes/metabolism Research and Reviews, vol. 26, no. 4, pp. 287–296, 2010.

P. Barrington, J. Y. Chien, F. Tibaldi, H. D. Showalter, K. Schneck, and B. Ellis, “LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects,” Diabetes, Obesity and Metabolism, vol. 13, no. 5, pp. 434–438, 2011.

K. Ban, M. H. Noyan-Ashraf, J. Hoefer, S. S. Bolz, D. J. Drucker, and M. Husain, “Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways,” Circulation, vol. 117, no. 18, pp. 2340–2350, 2008.

F. J. Service and P. C. O'Brien, “The relation of glycaemia to the risk of development and progression of retinopathy in the diabetic control and complications trial,” Diabetologia, vol. 44, no. 10, pp. 1215–1220, 2001.

World Health Organization, “Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus,” 1999, Geneva, Report Number: WHO/NCD/NCS/99.2.

R. Kawamori, F. G. Eliaschewitz, H. Takayama, and C. Y. Hayashida, “Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus,” Diabetes Research and Clinical Practice, vol. 79, no. 1, pp. 97–102, 2008.

L. Blonde, J. Jendle, J. Gross et al., “Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study,” The Lancet, vol. 385, no. 9982, pp. 2057–2066, 2015.

J. Jendle, M. A. Testa, S. Martin, H. Jiang, and Z. Milicevic, “Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD-4 substudy,” Diabetes, Obesity and Metabolism, vol. 18, no. 10, pp. 999–1005, 2016.

J. L. Probstfield, “Glucose variability in a 26-week randomized comparison of mealtime treatment with rapid-acting insulin versus GLP-1 agonist in participants with type 2 diabetes at high cardiovascular risk,” Diabetes Care, vol. 39, no. 6, pp. 973–981, 2016.

J. H. DeVries, “Glucose variability: where it is important and how to measure it,” Diabetes, vol. 62, no. 5, pp. 1405–1408, 2013.

M. Abdul–Ghani, O. Migahid, A. Megahed et al., “Combination therapy with exenatide plus pioglitazone versus basal/bolus insulin in patients with poorly controlled type 2 diabetes on sulfonylurea plus metformin: the qatar study,” Diabetes Care, vol. 40, no. 3, pp. 325–331, 2017.

G. Umpierrez, S. Tofe Povedano, F. Perez Manghi, L. Shurzinske, and V. Pechtner, “Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3),” Diabetes Care, vol. 37, no. 8, pp. 2168–2176, 2014.

M. Nauck, R. S. Weinstock, G. E. Umpierrez, B. Guerci, Z. Skrivanek, and Z. Milicevic, “Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5),” Diabetes Care, vol. 37, no. 8, pp. 2149–2158, 2014.

F. Giorgino, M. Benroubi, J. H. Sun, A. G. Zimmermann, and V. Pechtner, “Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2),” Diabetes Care, vol. 38, no. 12, pp. 2241–2249, 2015.

E. Araki, N. Inagaki, Y. Tanizawa, T. Oura, M. Takeuchi, and T. Imaoka, “Efficacy and safety of once-weekly dulaglutide in combination with sulphonylurea and/or biguanide compared with once-daily insulin glargine in Japanese patients with type 2 diabetes: a randomized, open-label, phase III, non-inferiority study,” Diabetes, Obesity and Metabolism, vol. 17, no. 10, pp. 994–1002, 2015.

J. Rosenstock, V. A. Fonseca, J. L. Gross et al., “Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro,” Diabetes Care, vol. 37, no. 8, pp. 2317–2325, 2014.

K. Esposito, F. Nappo, R. Marfella et al., “Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress,” Circulation, vol. 106, no. 16, pp. 2067–2072, 2002.

M. Diamant, M. A. Nauck, R. Shaginian et al., “Glucagon-like peptide 1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes,” Diabetes Care, vol. 37, no. 10, pp. 2763–2773, 2014.

C. Wysham, T. Blevins, R. Arakaki et al., “Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1),” Diabetes Care, vol. 37, no. 8, pp. 2159–2167, 2014.

M. A. Nauck, J. L. Frossard, J. S. Barkin et al., “Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide,” Diabetes Care, vol. 40, no. 5, pp. 647–654, 2017.

A. E. Butler, R. Galasso, A. Matveyenko, R. A. Rizza, S. Dry, and P. C. Butler, “Pancreatic duct replication is increased with obesity and type 2 diabetes in humans,” Diabetologia, vol. 53, no. 1, pp. 21–26, 2010.